We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · October 01, 2019

Nemolizumab in Adults With Moderate/Severe Atopic Dermatitis and Severe Pruritus

Journal of Allergy and Clinical Immunology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Allergy and Clinical Immunology
Phase 2b Randomized Study of Nemolizumab in Adults With Moderate-Severe Atopic Dermatitis and Severe Pruritus
J. Allergy Clin. Immunol 2019 Aug 23;[EPub Ahead of Print], JI Silverberg, A Pinter, G Pulka, Y Poulin, JD Bouaziz, A Wollenberg, DF Murrell, A Alexis, L Lindsey, F Ahmad, C Piketty, A Clucas

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading